BridgeMD
New treatment option for PSC
Official title Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis
ClinicalTrials.gov ID: NCT06865924
What this study is testing
- What it's testing
- Primary sclerosing cholangitis (PSC) is a rare, progressive and often fatal disease of the intrahepatic or extrahepatic bile ducts, with an estimated prevalence in Western countries of 1/10,000. Biliary disease in PSC is represented by cholestasis, chronic inflammation of the bile ducts, the small tubes through which bile passes, progressive concentric fibrosis around the bile ducts2.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- Between 18 and 90 years of age
- Of both sexes
- willingness to sign informed consent for the study; Additional criteria group 1
- Patients with a confirmed aPSC diagnosis Additional criteria group 2
- patients with suspected PSC liver biopsy candidates Additional criteria group 3
You likely can't join if
- -Positive for chronic viral hepatitis (HCV-RNA and HBsAg).
See the full eligibility criteria
- Between 18 and 90 years of age
- Of both sexes
- willingness to sign informed consent for the study; Additional criteria group 1
- Patients with a confirmed aPSC diagnosis Additional criteria group 2
- patients with suspected PSC liver biopsy candidates Additional criteria group 3
- Patients not affected by aPSC listed for the following procedures:
- Liver resection for hepatocellular or other hepatic lesions (including secondary effects from other cancers and benign focal lesions, which will result in healthy liver tissue);
- Post-transplant biopsies of healthy liver;
- cholecystectomies. Additional criteria group 4
- Patients previously genotyped in the study "Impact of complete exoma sequencing on clinical management of patient with non-alcoholic liver steatosis and cryptogenic liver disease project code RF-2016-02364358" results...
- -Positive for chronic viral hepatitis (HCV-RNA and HBsAg).
The study team makes the final eligibility decision.
Where it's taking place
- Milan, MI, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Milan, MI, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.